Intellia Therapeutics (NTLA) Tops Q2 EPS by 8c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Intellia Therapeutics (NTLA) Tops Q2 EPS by 8c, Revenues Beat

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

August 6, 2020 7:30 AM EDT

Submitted first regulatory application to the U.K.s MHRA to initiate a Phase 1 study of NTLA-2001 for the treatment of transthyretin amyloidosis; on track to dose first patient by year-end Expanded Regeneron collaboration, receiving $100 million through upfront cash and equity investment and agreeing to co-develop treatments for hemophilia A and B using CRISPR-mediated targeted transgene insertion technology On track to submit an IND or IND-equivalent in 2021 for each of two wholly owned programs: NTLA-5001 for the treatment of acute myeloid leukemia and NTLA-2002 for the treatment of hereditary angioedema... More